Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial ResultsPRNewsWire • 02/27/24
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid TumorsPRNewsWire • 02/12/24
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferencePRNewsWire • 02/01/24
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated MilestonesPRNewsWire • 01/08/24
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial ResultsPRNewsWire • 11/14/23
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology DayPRNewsWire • 11/01/23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLCPRNewsWire • 10/13/23
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety ProfilePRNewsWire • 10/04/23
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC SymposiumPRNewsWire • 09/18/23
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid TumorsPRNewsWire • 09/05/23
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial ResultsPRNewsWire • 08/10/23
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's WhyZacks Investment Research • 07/21/23
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 06/07/23